Valye reports for unlimited access

Mediaco Holding Inc. is a media company incorporated in Indiana with principal offices in New York City. The company operates through subsidiaries including MediaCo Operations LLC and acquired substantially all assets of Estrella Broadcasting, Inc. in April 2024. Its business includes television and radio broadcasting, with network affiliation and supply agreements that terminated in May 2025. Mediaco has entered into financing arrangements including a first lien term loan credit facility of up to $45 million and a second lien term loan credit facility of $30 million, both maturing in 2029. The company has a shareholders' agreement with SG Broadcasting and SLF LBI Aggregator, granting certain board designation rights and consent rights to Aggregator. Operational support is provided through agreements with Standard Media Group LLC, an affiliate of controlling shareholder SG Broadcasting. As of June 30, 2026, Mediaco had cash and cash equivalents of approximately $1.81 million, current assets of $34.2 million, and current liabilities of $156.2 million, resulting in liquidity ratios indicating a current ratio of 0.22 and a cash ratio of 0.01. The company reported a net loss of $1.3 million for the fiscal year ended December 31, 2024, and negative earnings per share of $0.10 for the quarter ended June 30, 2026. Leadership includes CEO Alberto Rodriguez appointed in November 2025, with recent appointments of Brian Fisher as President and Roberto Castro as Interim CFO in July 2026. The company announced a strategic partnership between EstrellaTV and EVTV Digital Network in January 2026 and has reported strengthening of its financial position and leadership in May 2026. Mediaco is classified as an emerging growth company.

All In FutureTech Alliance, Inc. is a global experiential entertainment company formerly known as Allied Gaming & Entertainment, Inc. It operates across esports venues, mobile gaming, content production, and emerging technology sectors. The company has repositioned from its prior ownership of the World Poker Tour to focus on a broader gaming lifestyle and digital ecosystem strategy. Key operations include the HyperX Arena Las Vegas esports venue, mobile gaming investments such as a controlling stake in Z-Tech, and educational initiatives through Allied International Futuretech Academy. The company is actively exploring AI infrastructure, digital connectivity, and super-computing opportunities to integrate with its entertainment and technology platforms [S1].

Avalon GloboCare Corp. is a technology-innovation company focused on consumer health and artificial intelligence content markets. It operates two segments: the consumer health technology segment distributes the Keto Air breathalyzer, a non-invasive device measuring ketosis levels with FDA registration, sold exclusively in North America. The AI content technology segment operates through Avalon Quantum AI, LLC, which was formed after acquiring RPM Interactive, Inc., a generative AI software company, in December 2025. The RPM platform automates short-form video content creation using AI avatars and is currently in beta testing with plans for broader commercial launch. The company has discontinued its THC breathalyzer development due to funding constraints but continues to maintain a portfolio of cellular therapy patents co-owned with MIT and Arbelli. Avalon GloboCare faces competition from larger and early-stage companies in both segments and is navigating regulatory and liquidity challenges.

Berto Acquisition Corp. II operates as a special purpose acquisition company (SPAC), which typically raises capital through an initial public offering to acquire or merge with an existing business. The company does not disclose any operating segments, revenue streams, or detailed business activities in the available filings. Its financial position as of June 30, 2026, shows a strong liquidity profile with cash and current assets significantly exceeding current liabilities. The net income reported for the quarter may reflect non-operating income or other financial activities typical of SPACs prior to a business combination.

byNordic Acquisition Corp is a special purpose acquisition company (SPAC) incorporated in Delaware, formed to complete an initial business combination with a technology growth company primarily located in Northern Europe. The company completed its initial public offering in February 2022, raising gross proceeds of approximately $150 million, which are held in a trust account. The management team has extensive experience in the targeted geographic region and technology sectors including FinTech, digital infrastructure, software including AI, health technology, sustainability/climate technology, transportation technology, and industrial technology. The company seeks to acquire targets with enterprise valuations primarily between $150 million and $750 million that have differentiated products or services addressing unmet needs and are ready to be public companies. The business combination deadline has been extended multiple times, currently set for August 12, 2026, with monthly extensions funded by the sponsor. The company reported a net loss and low liquidity ratios as of June 30, 2026, reflecting ongoing operational costs and the absence of a completed business combination [S1][S2].

BioNexus Gene Lab Corp is a Wyoming-based holding company with two main subsidiaries operating in Malaysia: Chemrex Corporation Sdn. Bhd., which distributes chemical raw materials primarily fiber reinforced polymers (FRP) for industrial applications across Southeast Asia, and MRNA Scientific Sdn. Bhd., which provides blood-based genomic screening services for early disease risk assessment. In November 2025, BioNexus expanded its strategic focus by acquiring exclusive rights to the VitaGuard™ minimal residual disease platform, an AI-enabled liquid biopsy system for cancer monitoring, through a licensing agreement with Fidelion Diagnostics. The company completed a reverse stock split in April 2025 to maintain Nasdaq listing compliance and has an equity distribution agreement for at-the-market offerings. Chemrex’s customer base includes manufacturers and fabricators with repeat business, and the company maintains strong supplier relationships. As of June 30, 2026, BioNexus reported modest revenue, a net loss, and a strong liquidity position with a current ratio above 6.0. Governance improvements are ongoing at Chemrex following identified lapses. Recent news reports indicate leadership changes and delisting risks, balanced by prior compliance regain and growth strategy initiatives.

ONAR Holding Corporation is a Nevada-based public company formed in 2014 and restructured through a reverse merger in 2024. It focuses on building a technology-enabled marketing platform by acquiring specialist marketing agencies targeting middle-market companies with revenues from $10 million to $1 billion. The company operates through its primary subsidiary ONAR, LLC, which owns JUICE, a performance digital marketing agency, and ONAR Labs, a technology division developing proprietary AI and data analytics platforms. JUICE provides full-spectrum digital marketing services across various sectors and has generated over $2.5 billion in client revenue. ONAR Labs supports the network with AI-driven tools for customer intelligence, campaign optimization, and quality assurance. The company has divested non-core legacy businesses and centralized back-office functions to improve operational efficiency. It has expanded its Board of Directors to include experienced independent members to strengthen governance. The marketing services industry is evolving rapidly with AI and data analytics, and ONAR positions itself to serve the growing middle market with integrated technology and marketing solutions [S1].

Firsthand Technology Value Fund, Inc. is a technology-focused investment fund that holds a portfolio of technology-related assets. The company’s publicly available information is limited, with recent SEC filings indicating a net loss and no detailed revenue or cash flow disclosures. The Fund is engaged in ongoing legal proceedings involving portfolio companies and management, which may impact its operations and governance. Recent news coverage does not provide direct insights into the Fund’s business activities or strategy.

Prairie Operating Co. operates primarily in the Denver-Julesburg Basin in Weld County, Colorado, focusing on crude oil, natural gas, and natural gas liquids. The company’s assets include approximately 45,000 net leasehold acres in its Central Weld Assets and 23,000 net leasehold acres in its Genesis Assets. It pursues growth through organic drilling and accretive acquisitions, emphasizing capital efficiency and environmental responsibility. The company employs advanced drilling technologies and maintains a disciplined capital allocation strategy. Its proved reserves totaled approximately 121.1 MMBoe as of December 31, 2025, with a PV-10 value of $1.22 billion. The company’s stock is listed on Nasdaq but is currently under notice for minimum bid price compliance [S1][S2][Q0].

Tivic Health Systems, Inc. operates in the biotechnology sector, focusing on the development and commercialization of proprietary TLR5 agonist therapies. The company holds exclusive worldwide licenses for Entolimod targeting Acute Radiation Syndrome and has options for additional indications such as Neutropenia. Its business model involves advancing clinical development milestones, managing licensing agreements with milestone and royalty payments, and preparing for commercialization. The company is an emerging growth company listed on Nasdaq and is currently managing compliance with listing requirements through a proposed reverse stock split.

Healthy Extracts Inc. operates in the nutraceutical sector, developing and commercializing innovative nutritional supplements and gel-based nutrition technologies. The company has demonstrated strong revenue growth in recent years, supported by strategic partnerships and acquisitions such as the merger with Gummy USA and collaboration with Gelteq. Its product portfolio includes formulations targeting specific health needs, including CoQ10 support for statin users and anti-aging supplements. The company actively markets its products through channels including Amazon and has secured significant follow-on orders from industry leaders. Financially, the company reported record revenues in 2025 but also shows liquidity challenges as of mid-2026, with current liabilities exceeding current assets and a net loss in the latest quarter.

Comscore, Inc. provides data and analytics services that measure advertising effectiveness, content consumption, and consumer audiences across various media platforms globally. The company generates revenue primarily through its Content & Ad Measurement solutions, which include Syndicated Audience and Cross-Platform services, and through Research & Insight Solutions. Its revenue is geographically diversified, with the majority derived from the United States, followed by Europe, Latin America, Canada, and other regions. Revenue recognition occurs both over time and at a point in time depending on the nature of the products and services. The company completed the divestiture of its Movies Business in May 2026 and continues to focus on enhancing its measurement capabilities through partnerships and technology investments.

Brag House Holdings, Inc. is a U.S.-based company operating a vertically integrated social network platform for non-professional college gamers and their fans. The platform facilitates competition among college gamers, fan support, and prize-winning opportunities. The company completed its IPO in March 2025 and has since focused on expanding its digital engagement offerings, including launching a digital asset platform to support its NIL initiative and monetization strategy. It has also developed gaming series in collaboration with collegiate athletics programs to enhance fan engagement. The company is engaged in a pending merger with House of Doge Inc., which involves related-party receivables and is subject to customary closing conditions. Financially, the company has reported significant losses and working capital deficiencies, with liquidity ratios indicating limited short-term asset coverage of liabilities as of mid-2026.

Patriot National Bancorp, Inc. is a registered bank holding company headquartered in Connecticut, with its principal asset being Patriot Bank, N.A. The Bank operates eight branches primarily in Connecticut and New York, with an additional office in California opened in 2026. The Bank's business model is focused on relationship-driven banking and specialized financial services targeting entrepreneurs, investors, fintech companies, and underbanked but creditworthy customers. The Company has undergone substantial transformation in capital structure, governance, and strategy since 2025, including a $50 million equity recapitalization and leadership changes. The Bank is subject to a Formal Agreement with the OCC requiring corrective actions to strengthen capital, governance, risk management, and compliance. Lending activities have been refocused on commercial real estate, high-net-worth credit lines, and asset-backed financing. Deposit and treasury management services support consumer, commercial, and institutional clients. The Bank operates in a competitive environment and is regulated by multiple federal agencies.

Franklin Solana Trust is a Delaware statutory trust formed in 2025 that offers the Franklin Solana ETF (SOEZ), a passive investment vehicle listed on NYSE Arca. The Fund seeks to track the price performance of Solana cryptocurrency and staking rewards by holding Solana assets, managed passively without leverage or derivatives. Shares represent fractional interests backed by Solana held in custody by Coinbase Custody Trust Company. The Fund issues and redeems shares in large blocks called Creation Units through authorized participants. The net asset value is calculated daily using a regulated benchmark index aggregating Solana spot prices from major exchanges. The Fund's expenses are primarily covered by a Sponsor fee of 0.19% annually. The Fund is not registered as an investment company or commodity pool and shareholders have limited voting rights. The Sponsor may terminate the Fund with notice.

INVO Fertility, Inc. is a publicly traded company on Nasdaq under the ticker IVF, operating in the fertility services sector. The company provides fertility-related medical services and products, including the INVOcell device. It has expanded its service offerings to include platelet-rich plasma therapy and telehealth services to improve access to fertility care. The company has undergone multiple reverse stock splits in recent years. Leadership includes CEO Steven Shum and CFO Terah Krigsvold. Financial disclosures as of June 30, 2026, show revenue of approximately $2.18 million and net income of $888,740, with liquidity ratios indicating a current ratio below 1.0 and a cash ratio of 0.3, reflecting current liabilities exceeding current assets.

VPR Brands, LP. is a Delaware limited partnership engaged in the design, marketing, and distribution of electronic cigarettes, vaporizers, pocket lighters, and hemp-derived cannabidiol products. The company owns a portfolio of patents and trademarks and operates several brands including DISSIM (pocket lighters), HONEYSTICK (vaporizers for essential oils and herbs), GOLD LINE (CBD products), and GRANDFADDA (cigar-style vapor products). It also licenses its intellectual property and develops private label manufacturing programs. The company’s operations are subject to extensive federal, state, and local regulations, particularly concerning electronic nicotine and hemp-derived products. It faces competition from large tobacco companies and smaller manufacturers in a niche and evolving market. Financially, the company reported revenues of $703,770 for Q2 2026 and a net loss of $353,447, with cash and equivalents of $2.14 million and a current ratio of 1.56 as of June 30, 2026 [S1][S2].

Brand Engagement Network Inc. develops enterprise-grade conversational AI solutions powered by its proprietary Engagement Language Model (ELM122). The platform integrates multiple AI modules enabling natural, context-aware interactions across modalities such as web, phone, and kiosks. Initially focused on healthcare, the company has expanded into hospitality, insurance, advertising, media, and automotive verticals. Its AI Agents connect to client data systems to provide personalized, compliant responses and execute tasks within workflows. The company emphasizes configurable safety, data protection, and customization to meet industry-specific requirements. Commercial development includes partnerships and deployments in multiple international markets. The company completed the acquisition of Cataneo GmbH in mid-2026 and is involved in ongoing litigation related to a terminated reseller agreement with AFG Companies, Inc.

Super League Enterprise, Inc. operates in the digital media and gaming sector, focusing on playable media and interactive advertising. The company has undergone significant corporate restructuring and capital raising efforts since 2025, led by CEO Matt Edelman. It completed a strategic acquisition of the Misfits Ads Division from Misfits Gaming Group in early 2026 to expand its marketing and measurement capabilities. The company’s financials as of mid-2026 show ongoing net losses but maintain liquidity through cash, short-term investments, and current assets exceeding current liabilities. The company has issued warrants that may impact future share count and stock price. The board comprises experienced executives and independent directors with backgrounds in media, investment banking, and technology.

CIM Real Estate Finance Trust, Inc. operates as a real estate finance company managed by CIM Real Estate Finance Management, LLC, affiliated with CIM Group, L.P. The company focuses on real estate lending and investment activities. It has a governance structure with a five-member board including independent directors and multiple committees overseeing audit, compensation, governance, and risk management. The company reported revenues of $111.0 million and a net loss of $30.1 million for the quarter ended June 30, 2026, with cash reserves of $218.8 million. The company’s shares are not publicly traded on an exchange, and it has approximately 437.5 million shares outstanding as of April 2026. The company’s operations and financial results are influenced by macroeconomic factors such as interest rates, inflation, geopolitical risks, and market volatility. It also faces operational risks related to technology, vendor dependencies, and cybersecurity. Hedging strategies are employed to manage market risks but carry their own risks and costs.

Modular Medical, Inc. develops and commercializes innovative insulin pumps aimed at increasing adoption among insulin-requiring diabetes patients by addressing the complexity, cost, and usability issues of existing pumps. Its flagship product, the Pivot tubeless patch pump, received FDA clearance in April 2026 and began initial U.S. commercial shipments in June 2026. The company targets both Type 1 and Type 2 diabetes markets, focusing on patients who have been deterred from pump use due to current product shortcomings. Modular Medical emphasizes affordability, ease of use, insurance reimbursement support, and patient education to expand the insulin pump market. The company faces significant competition from established insulin pump manufacturers and has a history of operating losses with ongoing capital needs.

Helix Acquisition Corp. III is a Cayman Islands exempted blank check company incorporated in September 2025. It is formed to complete an initial business combination with one or more target companies, focusing on healthcare or healthcare-related industries. The company has not commenced operations or generated revenue and holds its IPO proceeds in a trust account until a business combination is completed or the trust is liquidated. The management team has experience in financing and public market transitions. The company completed its IPO in January 2026, raising $172.5 million including a private placement to its sponsor. It maintains strong liquidity and reported net income in the latest quarter, reflecting administrative activities rather than operating income.

Axe Compute Inc. is a technology company that, since late 2025, has focused on providing GPU compute capacity for artificial intelligence and high-performance computing workloads through a distributed network model primarily leveraging the Aethir network. The company also manages a digital asset treasury strategy centered on the Aethir token (ATH), which it acquires and stakes to generate yield and support its compute services. The company operates an asset-light model but has recently expanded to owning and operating GPU computing hardware in data centers, which requires significant capital investment. The legacy business segment applies AI and a proprietary biobank of tumor samples to support oncology drug discovery, though strategic alternatives for this segment are being explored. The company’s compute services are delivered under prepaid contracts, with pricing based on GPU usage. The treasury strategy integrates with compute services by using ATH tokens as a settlement mechanism, creating a compounding economic relationship. The company’s financial position as of mid-2026 includes a net loss and moderate liquidity ratios. The business faces risks typical of capital-intensive technology infrastructure providers, including supply chain, operational, regulatory, and market demand risks.

Bone Biologics Corp focuses on developing bone regeneration medical devices centered on its proprietary recombinant human protein NELL-1 combined with demineralized bone matrix (DBM). The lead product candidate, NB1, targets lumbar spinal fusion surgery, aiming to improve bone growth outcomes with a safer and more targeted approach than existing treatments. The company holds exclusive worldwide rights to NELL-1 technology licensed from UCLA TDG and has advanced through preclinical validation in animal models to a pilot clinical trial in Australia. NB1 is designed to be used with existing spinal fusion hardware without altering surgical protocols. Bone Biologics operates in a highly regulated environment requiring FDA pre-market approval and faces competition from established orthopedic and biotech companies. The company has conducted multiple equity financings to fund ongoing development and operations.

Mountain Crest Acquisition Corp. V is a blank check company incorporated in Delaware in April 2021, focused on completing a business combination with a target company primarily in North America and Asia Pacific regions, excluding China. The company completed its initial public offering in November 2021, raising proceeds to be held in a trust account for the purpose of a future business combination. The company has not generated revenues or engaged in operations beyond organizational activities. It initially entered into a business combination agreement with AUM Biosciences, which was terminated in June 2023. Subsequently, MCAG entered into a definitive agreement with CUBEBIO Co., Ltd., a Korea-based in-vitro diagnostic company specializing in early cancer detection technology, aiming to become publicly listed through MCAG. The company has experienced Nasdaq listing compliance issues related to market value and timely SEC filings but has submitted plans and regained compliance. Its management team has extensive experience in SPACs and public company operations. The company’s financial position includes cash and investments held in trust accounts intended for the business combination, with limited liquidity outside the trust account as of mid-2026.

Nu Ride Inc. is a Delaware-incorporated company headquartered in New York City that emerged from Chapter 11 bankruptcy in March 2024. The company is governed by a board appointed by the official equity committee post-bankruptcy, with experienced directors including the CEO Alexander C. Matina. The company maintains a Code of Business Conduct and Ethics applicable to all employees and directors. Financially, as of June 30, 2026, Nu Ride reported strong liquidity with over $21 million in cash and equivalents and a current ratio exceeding 40, alongside a net loss for the quarter. The company has disclosed no material changes to its risk factors since its 2025 Annual Report.

Mobiquity Technologies, Inc. develops and operates proprietary software platforms for digital advertising execution, audience analytics, and publisher monetization with integrated privacy compliance. Its core platforms include ATOS, a programmatic advertising operating system leveraging AI and machine learning; MobiExchange, a SaaS data intelligence platform aggregating diverse data types for analytics; and CMOne, a publisher platform for monetization and compliance. The platforms can function independently or as an integrated stack. The company generates revenue primarily through platform licensing and managed services, serving advertising agencies, brands, publishers, and other ad tech companies. Mobiquity has a strategic partnership with Context Networks to deliver targeted advertising within casino gaming environments, converting gaming devices and venue screens into digital advertising inventory. The company is evolving toward an AI-powered customer acquisition platform, GrowthOS™, which integrates customer intelligence (GeoIntel™), AI decisioning (CMOne™), and campaign activation (ATOS™) into a unified system. GrowthOS supports multiple revenue streams including SaaS subscriptions, platform licensing, managed services, AI marketing solutions, and strategic partnerships. Management focuses on expanding GrowthOS adoption, enhancing AI capabilities, and growing recurring revenue. The company has reported increasing revenues in 2026 but continues to operate at a loss with liquidity challenges.

iSpecimen Inc. is a technology-driven company that operates the iSpecimen Marketplace, a global online platform designed to connect life science researchers with healthcare providers to procure human biospecimens and associated data for research. The platform consolidates a highly fragmented biospecimen procurement market by providing a single-source, searchable marketplace with integrated workflows from inquiry to invoice. It harmonizes de-identified patient and specimen data from a diverse network of healthcare providers, enabling researchers to efficiently find and acquire specimens that meet specific study criteria. The company generates revenue by procuring specimens from its healthcare provider network and distributing them to researchers, sharing revenue with providers based on specimen type and data provided. iSpecimen has invested in modernizing its technology infrastructure, transitioning to a cloud-native platform built on SalesStack to enhance scalability, security, and operational efficiency. The company continues to develop platform capabilities including enhanced search, workflow automation, and direct pricing to improve user experience and marketplace liquidity. As of mid-2026, iSpecimen reported limited revenue, ongoing net losses, and liquidity challenges, with management expressing substantial doubt about its ability to continue as a going concern. Recent strategic initiatives include a $2.5 million private placement to support marketplace expansion and completion of a digital transformation milestone. Operational improvements such as significant reductions in shipping times have been implemented. The company serves a diverse customer base including biopharmaceutical companies, diagnostic firms, and government and academic institutions, with a global footprint in specimen distribution and supply.

Mountain Crest Acquisition 6 Corp. operates as a Special Purpose Acquisition Company (SPAC), primarily focused on identifying and completing a business combination with a target company. As a SPAC, it holds capital raised from its IPO to facilitate a merger or acquisition but does not have significant ongoing operations or revenue-generating activities disclosed. The company’s financial snapshot as of mid-2026 shows a low current ratio and a net income figure, which may reflect accounting or non-operational items rather than core business earnings. The company’s risk disclosures reference its IPO prospectus, indicating no material changes in risk factors.

authID Inc. develops and provides biometric authentication and identity management platforms aimed at enhancing security and compliance for enterprises. Its product portfolio includes solutions such as PrivacyKey™, designed to secure biometric data. The company serves clients including global retailers, with partnerships to deliver high-assurance identity onboarding and privileged access protection. authID's revenue is concentrated among a few customers, reflecting dependency risks. The company operates with a history of net losses and negative cash flows, investing in growth initiatives and capital raising to sustain operations. authID's common stock trades on the Nasdaq Capital Market under the ticker AUID.

PetVivo Holdings, Inc. operates as a biomedical device company specializing in veterinary medical devices and therapeutics for companion animals such as dogs, cats, and horses. The company leverages proprietary biomaterials composed of natural proteins and carbohydrates to develop products that simulate body tissues, enhancing biocompatibility and integration. Its lead product, Spryng®, is designed to treat osteoarthritis by providing a bio-integrative scaffold within affected joints, promoting restoration of joint mechanics. Spryng® is administered via intra-articular injection and has been commercially available since 2022. The company holds a robust intellectual property portfolio including patents and trade secrets. Manufacturing is conducted in ISO-certified clean rooms with plans to expand capacity. Distribution has transitioned from exclusive agreements to multiple wholesale partnerships. PetVivo also pursues clinical studies to support product adoption and plans to expand its product pipeline through acquisitions and licensing.

HealthLynked Corp is a healthcare technology company focused on improving patient care management, operational efficiency of medical practices, and leveraging healthcare data for better outcomes. The company operates three divisions: Digital Healthcare, which manages the HealthLynked Network platform with AI-enabled tools, telemedicine, and concierge services; Health Services, which currently operates a single functional medicine practice while divesting other clinical operations; and Medical Distribution, which operates MedOfficeDirect LLC, a virtual distributor of medical supplies through an online marketplace. The company aims to create a complementary healthcare ecosystem that supports patient engagement and care coordination through technology.

Liminatus Pharma, Inc. is a publicly traded company engaged in a merger transaction with InnocsAI LLC, which involved issuing a combination of common stock and non-voting convertible preferred stock as merger consideration. The company has undertaken capital raising activities including warrant exercises and a $4 million offering of shares and warrants. It is listed on the Nasdaq Capital Market as of August 2026. The company is classified as an emerging growth company and reported a net loss and negative earnings per share for the quarter ended June 30, 2026. Liquidity metrics indicate a current ratio slightly above 1, with limited cash or short-term investments disclosed.

FiEE, Inc. is a digital service provider that completed a business transformation in 2025, moving away from its legacy networking hardware business. Its current operations focus on integrating artificial intelligence and data analytics into digital content services, software development, and digital authentication. The company generated $6.2 million in service fees and achieved profitability in 2025. FiEE's financial position as of mid-2026 shows positive net income and strong liquidity ratios, reflecting operational progress in its new business lines. The company is actively managing risks related to market competition, technological change, and regulatory compliance in the evolving digital services sector.

Bally's Corp operates primarily in the gaming and casino sector, with operations reflected in its SEC filings. The company manages liquidity with significant cash reserves but faces current liabilities exceeding current assets as of mid-2026. Bally's has a structured cybersecurity framework integrated into its overall risk management, including compliance with PCI-DSS and alignment with ISO standards. The company is overseen by a dedicated cybersecurity management team and Board-level committees focused on risk assessment and mitigation.

Stemtech Corp is a smaller reporting company with limited public disclosure on its business operations and industry classification. The company has ongoing legal proceedings related to a former CEO's claims and is in default on certain financing agreements. Financial data from recent SEC filings shows revenue of approximately $4.9 million for 2023 and a net loss in the second quarter of 2026. Liquidity ratios indicate significant current liabilities relative to current assets as of June 30, 2026.